Four New Rodent Pain Models Now Available
Aug 28 2013
As part of our work to translate early stage data into later stage clinical results, Charles River is investing in the development of ‘translational’ disease models in major therapeutic areas to meet our clients’ needs.
Our four new pain models focus on neuropathic, inflammatory and chronic joint pain indications.
The rodent formalin model is widely utilized as an acute and rapid in vivo screening assay for evaluating the potential analgesic effects of novel chemical entities. Video capture and off-line analysis of nocifensive behavior improves the data quality and reduces inter-experimenter variation.
The spinal nerve ligation (SNL) model is considered as one of the most suitable models for analgesia screening against neuropathic pain.
The rat paw CFA model is well characterized in literature and is routinely used for screening of novel compounds targeted for inflammatory pain.
Injection of the glycolytic inhibitor, monoiodoacetate (MIA) into the rodent’s joint causes behavioral, histological and biochemical changes many of which resemble human osteoarthritis (OA) and its associated joint pain. The rat MIA model is, thus, considered as a ‘translational’ model for OA-associated pain.
Of particular interest is the rat monoiodoacetate (MIA) model for osteoarthritis and chronic joint pain. Designed in combination with a dynamic weight bearing measurement system to gather more clinically relevant data, our rat MIA model mimics the symptoms of osteoarthritis. Using a pressure-sensitive sensor mat, video imaging and software analysis, Charles River scientists can assess the impact of investigational compounds on joint pain by measuring how the drug alleviates pain upon movement, which is a clinically relevant endpoint for patients with osteoarthritis pain.